目的：回顾性分析细胞因子诱导的杀伤（CIK）细胞联合化疗治疗晚期胰腺癌患者的疗效及安全性。方法：搜集2010年9月至2016年2月就诊于郑州大学附属肿瘤医院生物免疫治疗科的28例晚期胰腺癌患者，这些患者接受吉西他滨和/或替吉奥化学药物治疗，在化疗结束1~3 d内回输体外培养的CIK细胞。观察指标为疾病进展(PD)率，疾病稳定(SD)率，部分缓解(PR)率，完全缓解(CR)率，中位生存期（mOS），6个月、12个月、18个月和24个月的生存率，疾病控制率（disease control rate, DCR)和不良反应。DCR包括CR、PR和SD。结果：28例患者中5例PR（17.86%），15例SD（53.57%），8例PD（28.57%），DCR为71.43％，mOS 15.41，6、12、18和24个月的生存率分别为85.71%、50.00%、39.28%和10.71%；主要不良反应为骨髓抑制、恶心、呕吐，给予对症处理后好转。结论：CIK细胞联合化疗是晚期胰腺癌患者安全、有效的治疗方法，患者不良反应小，耐受性良好，可显著延长患者生存时间。

Objective:To analyze retrospectively the clinical efficacy and safety of the cytokine induced killer (CIK) cells combined with chemotherapy for the patients with advanced pancreatic carcinoma. Methods: Twenty eight patients with advanced pancreatic carcinoma who were hospitalized in Department of biotherapy, Tumor Hospital Affiliated to Zhengzhou University during September 2010 to February 2016 were collected. All of the patients received chemical treatment with gemcitabine and/or S-1. CIK cells cultured in vitro were transfused into the patients within 1 to 3 days after the chemotherapy. Rates of progressive disease (PD), stable disease (SD), partial regression (PR) and complete regression (CR), median overall survival ( mOS), rates of survival for 6 months、12 months、18 months and 24 months, disease control rate (DCR) and adverse effects were observed. DCR included CR, PR and SD. Results: Among the 28 patients, PR rate 17.86% (5 cases), SD rate 53.57% (15 cases) and PD rate 28.57% (8 cases) respectively. DCR was 7143%. mOS was 15.41 months. Rates of survival for 6 months、12 months、18 months and 24 months respectively were 85.71%,50.00%,39.28% and 10.71%. The major adverse effects were myelo suppression，nausea and emeses, which were improved after symptomatic treatments. Conclusion: The CIK cells combined with chemotherapy could be an effective and safety treatment approach for the patients with advanced pancreatic carcinoma. The patients might have little adverse reactions and well toleration. The treatment approach could markedly prolong survival of the patients.